Real-world burden of chemotherapy-induced myelosuppression in patients with small cell lung cancer: a retrospective analysis of electronic medical data from community cancer care providers
- PMID: 34927520
- DOI: 10.1080/13696998.2021.2020570
Real-world burden of chemotherapy-induced myelosuppression in patients with small cell lung cancer: a retrospective analysis of electronic medical data from community cancer care providers
Abstract
Aims: Chemotherapy-induced myelosuppression, which commonly exhibits as neutropenia, anemia, or thrombocytopenia, represents a substantial burden for patients with cancer that affects health-related quality of life and increases healthcare resource utilization (HCRU). We evaluated the burden of myelosuppression among chemotherapy-treated patients with small cell lung cancer (SCLC) using real-world data from community cancer care providers in the Western United States.
Materials and methods: This was a retrospective, observational analysis of electronic medical records (EMRs) from Providence St. Joseph Health hospital-associated oncology clinics between January 2016 and December 2019. Patient demographics were assessed from the date of first SCLC diagnosis in adult patients with chemotherapy-induced grade ≥3 myelosuppression in first-line (1L) or second-line-and-beyond (2L+) treatment settings. Myelosuppressive adverse events (AEs), treatment patterns, and HCRU were assessed from the date of chemotherapy initiation (index date) until 12 months, date of the last visit, date of death, or study end, whichever occurred earliest.
Results: Of 347 eligible patients with SCLC who had received chemotherapy (mean age 66; 49% female), all had received at least 1L treatment, and 103 (29.7%) had a 2L + treatment recorded within the EMR during the study period. Of 338 evaluable patients with longitudinal laboratory data, 206 (60.9%) experienced grade ≥3 myelosuppressive AEs, most commonly neutropenia, anemia, and thrombocytopenia (44.9, 41.1, and 25.4 per 100 patients, respectively). Rates of granulocyte colony-stimulating factor use and red blood cell transfusions were 47.0 and 41.7 per 100 patients, respectively. There was a trend toward increasing the use of supportive care interventions and visits to inpatient and outpatient facilities in patients with myelosuppressive AEs in more than one cell lineage.
Conclusions: Chemotherapy-induced myelosuppression places a substantial real-world burden on patients with SCLC in the community cancer care setting. Innovations to protect bone marrow from chemotherapy-induced damage have the potential to reduce this burden.
Keywords: Chemotherapy; I; I00; I1; I11; healthcare resource use; hematologic toxicity; myelosuppression; small cell lung cancer; supportive care.
Plain language summary
PLAIN LANGUAGE SUMMARYThis study looked at the medical records of people with a particular type of lung cancer known as small cell lung cancer. When treated with chemotherapy, people with this cancer may develop a condition called myelosuppression. This causes people to have fewer blood cells, which can lead to tiredness, or increase the risk of infection or bleeding. The study looked at what types of chemotherapy people with small cell lung cancer were given, what the side effects of myelosuppression were, how often the side effects were reported, and what treatments were given to manage these side effects. The study also looked at whether people with side effects from myelosuppression needed more visits to the doctor or hospital. Around 3 out of 5 people in the study experienced serious side effects resulting in reduced numbers of white blood cells (which fight infection), red blood cells (which carry oxygen), or platelets (which help the blood to clot), and many needed drugs or blood transfusions to treat these side effects. On average, people with side effects from myelosuppression had more visits to healthcare facilities than those people without these side effects. The findings suggest that myelosuppression places a large burden on people with small cell lung cancer who are treated with chemotherapy.
Similar articles
-
Burden of chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer: A retrospective study from community oncology practices.Cancer Med. 2023 Apr;12(8):10020-10030. doi: 10.1002/cam4.5738. Epub 2023 Mar 31. Cancer Med. 2023. PMID: 37000119 Free PMC article.
-
Patient Burden and Real-World Management of Chemotherapy-Induced Myelosuppression: Results from an Online Survey of Patients with Solid Tumors.Adv Ther. 2020 Aug;37(8):3606-3618. doi: 10.1007/s12325-020-01419-6. Epub 2020 Jul 8. Adv Ther. 2020. PMID: 32642965 Free PMC article.
-
Burden of chemotherapy-induced myelosuppression among patients with ES-SCLC in US community oncology settings.Future Oncol. 2022 Nov;18(35):3881-3894. doi: 10.2217/fon-2022-0754. Epub 2022 Nov 15. Future Oncol. 2022. PMID: 36377828
-
The impact of myelosuppression on quality of life of patients treated with chemotherapy.Future Oncol. 2024 Apr 8:1-16. doi: 10.2217/fon-2023-0513. Online ahead of print. Future Oncol. 2024. PMID: 38587388 Review.
-
New Advances in Supportive Care: Chemoprotective Agents as Novel Opportunities in Geriatric Oncology.Curr Oncol Rep. 2022 Dec;24(12):1695-1703. doi: 10.1007/s11912-022-01324-x. Epub 2022 Aug 20. Curr Oncol Rep. 2022. PMID: 35986858 Review.
Cited by
-
Real-World Outcomes of Trilaciclib Among Patients with Extensive-Stage Small Cell Lung Cancer Receiving Chemotherapy.Adv Ther. 2023 Oct;40(10):4189-4215. doi: 10.1007/s12325-023-02601-2. Epub 2023 Jul 25. Adv Ther. 2023. PMID: 37490258 Free PMC article. Review.
-
Construction of an auxiliary scoring model for myelosuppression in patients with lung cancer chemotherapy based on random forest algorithm.Am J Transl Res. 2023 Jun 15;15(6):4155-4163. eCollection 2023. Am J Transl Res. 2023. PMID: 37434857 Free PMC article.
-
The efficacy and safety of Trilaciclib in preventing chemotherapy-induced myelosuppression: a systematic review and meta-analysis of randomized controlled trials.Front Pharmacol. 2023 May 25;14:1157251. doi: 10.3389/fphar.2023.1157251. eCollection 2023. Front Pharmacol. 2023. PMID: 37305548 Free PMC article.
-
Drivers of Emergency Department Use Among Oncology Patients in the Era of Novel Cancer Therapeutics: A Systematic Review.Oncologist. 2023 Dec 11;28(12):1020-1033. doi: 10.1093/oncolo/oyad161. Oncologist. 2023. PMID: 37302801 Free PMC article.
-
A multicenter phase II trial of primary prophylactic PEG-rhG-CSF in pediatric patients with solid tumors and non-Hodgkin lymphoma after chemotherapy: An interim analysis.Cancer Med. 2023 Jul;12(13):14130-14137. doi: 10.1002/cam4.6079. Epub 2023 May 15. Cancer Med. 2023. PMID: 37183837 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical